Clinical Trials
32 trialsPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
MK-4280A-008
Merck Sharp & Dohme LLC
HL-R2-B2
University Hospital, Bordeaux
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Emory University
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
St. Petersburg State Pavlov Medical University
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Shanghai Junshi Bioscience Co., Ltd.
CheckMate 744
Bristol-Myers Squibb
BURGUND
Polish Lymphoma Research Group
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Dalian Medical University
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
Prolgo-HL
St. Petersburg State Pavlov Medical University
FUSION NHL 001
Celgene
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Tessa Therapeutics
Compassionate Use Re-Infusion of ATLCAR.CD30
UNC Lineberger Comprehensive Cancer Center
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Weill Medical College of Cornell University
SGN+Benda
Columbia University
NB001
St. Petersburg State Pavlov Medical University
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
University of California, Davis
TREC
University of Washington
BeEAC-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
LEBEN
GiovanniPascale
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas